DREAMM-2 demonstrates meaningful ORR with belantamab mafodotin in multiple myeloma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Treatment with the investigational single-agent belantamab mafodotin resulted in a 31% overall response rate with the 2.5 mg/kg regimen in patients with heavily pre-treated multiple myeloma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login